Alvotech Gets FDA Letter, Expects Delay in U.S. Approval of AVT02
By Mary de Wet
Alvotech said Wednesday that approval for AVT02, a biosimilar candidate for Abbvie's Humira, in the U.S. is likely to be delayed after the Icelandic company received a complete response letter from the Food and Drug Administration.
As a result, Alvotech said it would explore options to raise additional capital to continue advancing pipeline development in the near term.
ATP Holdings, a unit of Alvotech's largest shareholder, Aztiq, is interested in providing as much as $100 million from potential financing, Alvotech said.
The FDA letter was in response to the company's second biologics license application. In April, the FDA sent Alvotech a complete response letter for its initial application, which noted certain deficiencies at the company's Reykjavik facility.
Alvotech said it intends to resubmit the biologics license application for AVT02.
Write to Mary de Wet at mary.dewet@dowjones.com
(END) Dow Jones Newswires
June 28, 2023 19:48 ET (23:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track